Inogen Inc 2025年季度报告

INOGEN, INC. (Exact name of registrant as specified in its charter) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange As of May 2, 2025, the registrant had26,887,242shares of common stock, par value $0.001, outstanding. TABLE OF CONTENTS Part I – Financial Information Item 1.Financial Statements Consolidated Balance Sheets (unaudited) as of March 31, 2025 and December 31, 2024Consolidated Statements of Comprehensive Loss (unaudited) for the Three Months Ended March 31, 2025 andMarch 31, 2024 Consolidated Statements of Stockholders’ Equity (unaudited) for the Three Months Ended March 31, 2025 and March 31, 20245Consolidated Statements of Cash Flows (unaudited) for the Three Months Ended March 31, 2025 and March Inogen, Inc.Consolidated Statements of Stockholders’ Equity Inogen, Inc.Condensed Notes to the Consolidated Financial Statements 1. Business overview Inogen, Inc., or the Company, is a medical technology business that primarily focuses on respiratory health. The Companydevelops, manufactures, and markets innovative respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeoxproduct for airway clearance treatment. The Company's proprietary Inogen One® around the patient to offer a source of supplemental oxygen 24 hours a day, seven days a week with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. While often used concomitantly with stationaryoxygen concentrators and oxygen compressed gas tanks, the Company's POCs are designed to reduce the patient’s reliance onstationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen, thereby improving patient quality of lifeand fostering mobility. The Company's Simeox product is a technology-enabled airway clearance and mucus management devicepredominantly aimed at serving patients with bronchiectasis, which is a condition that presents as the lung's bronchi are damaged The Company was incorporated in Delaware on November 27, 2001. On February 14, 2014, the Company completed an initialpublic offering of common stock and began trading on the Nasdaq Global Select Market, trading under the ticker symbol “INGN”. The Company incorporated Inogen Europe Holding B.V., a Dutch limited liability company, onApril 13, 2017. On May 4, 2017,Inogen Europe Holding B.V. acquired all issued and outstanding capital stock of MedSupport Systems B.V., or MedSupport, andbegan operating under the name Inogen Europe B.V. The Company merged Inogen Europe Holding B.V. and Inogen Europe B.V.on December 28, 2018. Inogen Europe B.V. is the remaining legal entity. The Company completed the acquisition of New Aera,Inc., or New Aera, on August 9, 2019. OnSeptember 14, 2023, the Company completed the acquisition of all of the issued and On January 25, 2025, the Company entered into a Strategic Collaboration Agreement, or the Collaboration Agreement, withJiangsu Yuyue Medical Equipment & Supply Co., Ltd., or Yuwell. The collaboration with Yuwell is expected to broaden theCompany's product portfolio through distribution of certain respiratory products in the United States and select other territories,expand and enhance the Company's innovation pipeline through research and development collaboration, and accelerate the entry 2. Basis of presentation and summary of significant accounting policies Basis of presentation The consolidated financial statements of the Company have been prepared in accordance with accounting principles generallyaccepted in the United States of America, or U.S. GAAP. The results of operations for the three months ended March 31, 2025 shown in this report are not necessarily indicative of results tobe expected for the full year ending December 31, 2025. In the opinion of the Company’s management, the information containedherein reflects all adjustments, consisting of only normal recurring a